兆科眼科－Ｂ (6622.HK)

1.550 -0.010 (-0.64%) 收市：03:57PM HKT

兆科眼科－Ｂ

No. 1 Meide 3rd Road
Pearl River Industrial Park Nansha District
Guangzhou
China
86 20 3906 2828
https://www.zkoph.com

版塊: Healthcare
行業: Biotechnology
全職員工: 313

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Xiaoyi Li Ph.D.	Chairman of the Board & CEO	10.78M	無	1963
Mr. Xiangrong Dai	Executive Director	783.1k	無	1981
Dr. Lit Fui Lau	President & Chief Scientific Officer	無	無	1964
Ms. Xinyan Feng	Chief Business Officer & CFO	無	無	1979
Ms. Yang Lei	Group General Counsel	無	無	1981
Dr. Mauro Bove Ph.D.	Senior Vice President of Corporate Development	無	無	1955
Mr. Jiang Feng	Senior Vice President of Sales & Marketing	無	無	1976
Dr. Albert Tsai Jr.	Chief Medical Officer	無	無	1974
Mr. Guohui Zhang	Senior Vice President of Manufacturing & Logistics	無	無	1974
Ms. Carol Liu	Group Head of Regulatory Affairs	無	無	1984

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.

公司管治

截至 無 止，兆科眼科－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。